The outlook of companies tied to flagship drugs like Viagra presents a challenging investment picture. While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial profits , the patent expiration in key regions has introduced considerable risk . Investors are now assessing the consequences of lower-cost a